Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07777328

The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements

The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements — Recruiting • Non-phase study • Mental Health / Psychiatry • NCT07777328.

📅 20 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07777328
Start
2025-11-25
Completion
2027-02
ClinicaliQ Trial Snapshot
  • The Effect of 5-hydroxytryptophan on ADHD Traits and Eye Movements — Recruiting • Non-phase study • Mental Health / Psychiatry • NCT07777328.
  • Trial testing whether a natural supplement (5-HTP) can improve concentration and attention problems by increasing serotonin levels.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The aim of this project is to look at the impact of 5-Hydroxytryptophan (5-HTP) on distractibility. 5-HTP is the precursor to the neurotransmitter serotonin and is a chemical that the body produces naturally. There is evidence that distractibility is associated with a decreased level of serotonin. This research aims to see if giving people 5-HTP will alter their distractibility, which will form part of an initial assessment as to whether 5-HTP could be used to support people with attention problems. The study involves completing a short survey about mental health…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
ADHD: Diagnosis and Management (NICE NG87)
Mental Health / Psychiatry · 27 Mar 2026
Refer suspected ADHD cases (presenting with inattention, hyperactivity, impulsivity, or functional impairment) to specialist services (paediatrician, psychiatrist, or specialist ADHD nurse) for…
View guideline →
Clinical Brief
Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction
Mental Health / Psychiatry · MHRA · 11 May 2026
The MHRA has identified suicidal thoughts and behaviours as a safety concern with finasteride and dutasteride, requiring additional risk minimisation measures in…
View brief →
Clinical Brief
NHS bosses warn of chaos in ADHD and autism care
Mental Health / Psychiatry · BBC Health · 28 Aug 2026
NHS leaders have raised concerns about escalating costs and service disruption driven by unregulated private ADHD and autism providers exploiting high patient…
View brief →
Clinical Brief
‘Don’t let blood be on your hands’, mother tells inquiry
Mental Health / Psychiatry · BBC Health · 14 Jul 2026
A mother's testimony at the Lampard Inquiry highlights systemic failures in mental health unit care that contributed to her daughter Elise Sebastian's…
View brief →
Clinical Brief
Mother and baby mental health unit to go ahead
Mental Health / Psychiatry · BBC Health · 30 Apr 2026
Northern Ireland will establish its first regional mother and baby unit within three years, addressing a significant gap in perinatal mental health…
View brief →
Clinical Brief
William and Catherine praise role of sports in suicide prevention
Mental Health / Psychiatry · BBC Health · 10 Sep 2026
The Prince of Wales is advocating for the sports sector to play an active role in suicide prevention, highlighting a potential gap…
View brief →